Cortigent Inc (CRGT) - יחס שווי פעילות לרווח לפני ריבית, מסים ופחת

Intellectual property protection via patents and strict FDA oversight create significant barriers to entry for Cortigent, Inc. (CRGT) competitors. Future growth depends on the success of trials for interfaces that restore vision and motor skills. This chart shows a market EV/EBITDA multiple of , confirming the efficiency of the fabless model, where device assembly is outsourced to US contractors to minimize infrastructure risks.

The investment attractiveness of Cortigent, Inc. (CRGT) is based on the potential of neuromodulation interfaces, which require significant external funding. The EV/EBITDA metric compares the total enterprise value, including net debt, with operating profit before depreciation and amortization, revealing the real value of assets regardless of the tax regime. By analyzing the Cortigent, Inc. (CRGT) EV/EBITDA chart on the GURU.Markets platform, an investor can assess the startup's fundamental stability in the absence of commercial sales.